research undisclosed pharma contributions center for social innovation csi skip to content center for social innovation csi center for social innovation az index find people visit admissions faculty & research alumni recruiters & companies news about the gsb search csi search the gsb home research undisclosed pharma contributions home research by topic student programs executive programs gsb social innovators community engagement events about csi more content blog social innovation podcast e newsletter videos follow us icon face book icon twitter research undisclosed pharma contributions author jessica ruvinsky stanford social innovation review fall 2011 topics global issues cover image fall 2011 tweet in 2007 eli lilly and company gave the national alliance on mental illness nami $450000 toward its campaign for the mind of america which if successful could greatly expand the market for lilly's newest and most expensive psychiatric drugs potential conflict of interest in the funding of health advocacy organizations haos by pharmaceutical companies is hard to suss out because those relationships are mostly not made public after doing a systematic analysis of the disclosure practices of haos i was very surprised at the large number of organizations that did not disclose industry contributions says sheila rothman a professor at columbia university's mailman school of public health although there is no general legal requirement for companies to do so as part of settlement agreements with the us read more subscription required you must be a subscriber to read this ssir article in its entirety subscribe at ssireview org related links subscribe admissions faculty & research alumni recruiters & companies giving executive education news about the gsb copyright 2009 stanford graduate school of business site help terms of use & policies stanford university
